4D Molecular (FDMT) recently shared encouraging interim results from its Phase 1/2 PRISM clinical trial, which is assessing the efficacy of 4D-150 in individuals with wet age-related macular degeneration (wet AMD). The data, covering a period of 1.5 to 3.5 years, highlights the sustained effectiveness of 4D-150 across three patient groups. Key outcomes include stable visual acuity, well-maintained retinal anatomy, and a decreased need for treatment interventions, with consistent benefits observed up to two years into the study.
The Phase 3 dose of 3E10 vg/eye shows strong promise according to this dose-response analysis. Importantly, 4D-150 remains well tolerated, with no new safety issues or intraocular inflammation noted, aligning with previous safety findings over a follow-up period extending to 3.5 years. Additionally, enrollment in the 4FRONT-1 Phase 3 trial has surpassed expectations, with over 200 participants already randomized. The enrollment process for the global 4FRONT-2 Phase 3 trial is progressing as planned, with completion anticipated in the second half of 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.